<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7174922\results\search\drug\results.xml">
  <result pre="to target SARS-CoV-2: Favipiravir [17], Galidesivir [18], Remdesivir [19] and" exact="Ribavirin" post="[20]. Interestingly, the docking site is not located in"/>
  <result pre="[21]. In addition, other possible drugs such as Filibuvir, Cepharanthine," exact="Simeprevir" post="and Tegobuvir, are predicted to be potential inhibitors of"/>
  <result pre="SARS-CoV-2 RdRp, including Favipiravir [17, 19], Galidesivir [18], Remdesivir [19]," exact="Ribavirin" post="[20], Penciclovir [31], Galidesivir [32] and Ponatinib [33]. Additionally,"/>
  <result pre="including Favipiravir [17, 19], Galidesivir [18], Remdesivir [19], Ribavirin [20]," exact="Penciclovir" post="[31], Galidesivir [32] and Ponatinib [33]. Additionally, other drugs"/>
  <result pre="[18], Remdesivir [19], Ribavirin [20], Penciclovir [31], Galidesivir [32] and" exact="Ponatinib" post="[33]. Additionally, other drugs such as Simeprevir (FDA approved"/>
  <result pre="Galidesivir [32] and Ponatinib [33]. Additionally, other drugs such as" exact="Simeprevir" post="(FDA approved HCV protease inhibitor), as well as Filibuvir"/>
  <result pre="interaction map reveals drug targets and potential drug-repurposingBioRxiv202010.1101/2020.03.22.002386 31.ManliWRuiyuanCLeikeZYangXLiuJXuMShiZHuZZhongWXiaoGRemdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="of a ribavirin-resistant NS5B mutation of hepatitis C virus during" exact="ribavirin" post="monotherapyHepatology200310.1053/jhep.2003.5044514512874 35.GoldhillDHte VelthuisAJWFletcherRALangatPZambonMLackenbyABarclayWSThe mechanism of resistance to favipiravir in"/>
 </snippets>
</snippetsTree>
